Proteomics International Laboratories (ASX:PIQ) has some interesting news pending, with the ASX granting the company a trading halt to prepare.
Proteomics is preparing results from the PromarkerD clinical validation study which will be presented at the American Diabetes Association conference on Saturday, 10 June 2017, in the U.S.
The halt will remain in place until the opening of trade on Wednesday 14th June 2017, or earlier if an announcement is made to the market.